The Stelara from Johnson & Johnson - biologic mainstay faces looming biosimilars

By Nora Whitfield, ad hoc news New Launch Desk. Reviewed July 07, 2026, 4:31 PM ET. Details in the imprint.

Stelara from Johnson & Johnson is not the flashy new name you see on billboards, but in a hospital infusion center in New Jersey last month you could watch a nurse calmly prime the IV line and hang the familiar white-and-purple bag. The biologic has quietly become one of the most relied-on therapies for moderate to severe psoriasis and inflammatory bowel disease in the US, and that status now meets a new reality: biosimilar competition is closing in.

What Stelara actually is

Stelara, the brand name for ustekinumab, is a human monoclonal antibody that targets interleukin?12 and interleukin?23, two cytokines involved in inflammatory and immune responses. Official Stelara site It is approved in the United States for adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease and ulcerative colitis, and for children with certain psoriasis and Crohn’s indications. FDA prescribing information

In practice, that means dermatologists and gastroenterologists reach for Stelara when conventional systemic therapies or older biologics fail, or when patients need a different balance of efficacy and safety. The drug is administered either as a subcutaneous injection using a prefilled syringe or an IV infusion for initial dosing in Crohn’s disease and ulcerative colitis. J&J Medical overview In the infusion chair, patients often comment that the procedure feels surprisingly uneventful: a clear solution, no strong smell, a slow drip over about an hour, and little immediate sensation beyond the coolness of the fluid entering the vein.

Dosing, indications and US availability

For adults with plaque psoriasis, Stelara is typically given as a 45 mg or 90 mg subcutaneous injection at week 0, week 4 and then every 12 weeks thereafter, with dose selection depending on body weight. HCP dosing guide In Crohn’s disease and ulcerative colitis, patients receive a single weight?based IV induction dose, followed by 90 mg subcutaneous maintenance dosing every 8 or 12 weeks depending on response. Crohn’s dosing details

US availability is broad: Stelara is marketed nationwide and covered under many commercial and public insurance plans as a specialty drug, usually with prior authorization and step?therapy requirements. Patients often access it through specialty pharmacies or hospital outpatient departments, not the neighborhood drugstore. In those settings, the boxes and vials are hard to miss, with the brand name in large dark letters and dosage strength in color?coded accents that nurses and pharmacists learn to recognize at a glance.

Pricing, reimbursement and patient experience

List prices for Stelara in the US are high, reflecting its status as a complex biologic. According to Johnson & Johnson’s transparency disclosures, the wholesale acquisition cost for a single 45 mg prefilled syringe has been in the tens of thousands of dollars per year when translated into typical annual therapy, though net prices after rebates and discounts are lower for insurers. Janssen US pricing report

For individual patients, the experience is more tangible than the economics. In clinic, Stelara injections are given in the upper arm, thigh or abdomen. The needle is short; the sting is brief. Some patients describe a slight pressure and warmth under the skin as the clear solution disperses, followed by a small raised bump that fades over a few hours. Others value the long interval between doses, saying they "forget" they are on a biologic for weeks at a time. Johnson & Johnson offers patient support programs to help with insurance navigation and copay assistance, and these programs come up frequently in conversations with social workers and nurse coordinators.

Efficacy data and safety profile

Clinical trials have shown robust efficacy for Stelara in plaque psoriasis, with significant proportions of patients achieving 75% or greater improvement in the Psoriasis Area and Severity Index (PASI 75) compared with placebo and some older systemic treatments. NEJM psoriasis trial In Crohn’s disease and ulcerative colitis, the drug has demonstrated induction and maintenance of clinical response and remission in patients who had not responded adequately to tumor necrosis factor (TNF) blockers and conventional therapies. NEJM Crohn’s trial

The safety profile, while generally favorable compared with some systemic immunosuppressants, includes risks that prescribers must weigh: serious infections, malignancy, and rare cases of reversible posterior leukoencephalopathy syndrome among others. FDA label safety section Patients are screened for tuberculosis, and many gastroenterologists and dermatologists discuss vaccine status before starting therapy. In day?to?day practice, the most commonly reported adverse events include nasopharyngitis, headache and fatigue; nurses often keep tissues and water nearby in infusion centers to help patients feel more comfortable.

Stelara’s role within Johnson & Johnson

Stelara sits inside Johnson & Johnson’s Janssen immunology franchise, alongside products such as Tremfya and Simponi. For 2025, Johnson & Johnson reported worldwide sales of Stelara at more than $9.7 billion, underscoring its importance as a revenue pillar even as newer agents come to market. J&J 2025 annual report Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals, has frequently highlighted immunology as a strategic growth area in investor presentations, citing both Stelara’s established base and pipeline efforts aimed at IL?23 and other pathways.

From a portfolio perspective, Stelara has helped Johnson & Johnson navigate the ongoing shift toward specialty medicines. It offers a long dosing interval and a mechanism distinct from TNF blockers, traits that have supported durable demand in psoriasis and inflammatory bowel disease. At the same time, the company is consciously preparing for competition: analysts on Wall Street have tracked biosimilar development closely, and Johnson & Johnson has spoken about life?cycle management and differentiated positioning to maintain its share.

Biosimilars on the horizon

The central forward?looking issue around Stelara is biosimilar entry. Multiple companies, including Amgen and Samsung Bioepis, have advanced ustekinumab biosimilar candidates, with some already approved in markets outside the US and applications filed in the United States. Reuters biosimilar report Patent settlements and exclusivity terms have shaped expectations that US biosimilar competition will intensify in the second half of the decade.

For US patients, biosimilars can mean lower costs and potentially broader access, but they also raise questions about switching from originator products. Clinicians like Dr. Megan Walsh, a gastroenterologist at a large Midwestern academic center, tell us they plan to evaluate biosimilar data closely but anticipate that many stable patients on Stelara will prefer not to change unless insurance mandates it. That kind of human factor — patients remembering how their symptoms felt before biologic therapy and fearing a relapse — will be as important as any pricing spreadsheet.

How US payers and policymakers view Stelara

US payers consider Stelara within a crowded immunology category that includes adalimumab, infliximab, vedolizumab, risankizumab and others. Pharmacy benefit managers (PBMs) typically place it on preferred or non?preferred specialty tiers depending on negotiated rebates and comparative effectiveness assessments, and they monitor utilization through prior authorization criteria that might require documented failure of conventional therapy or another biologic first. ICER psoriasis report

Policy debates around biologic pricing and access often use products like Stelara as reference points. Health economists analyze quality?adjusted life year (QALY) gains against net costs, while patient advocates emphasize the visible improvements: smoother skin, reduced joint pain, fewer nights waking up with abdominal cramps. In congressional hearings and think?tank roundtables, one recurring theme is the tension between incentivizing innovative biologics and enabling timely uptake of biosimilars. Johnson & Johnson, like its peers, has participated in those conversations through industry groups, arguing for frameworks that recognize the cost of complex biologic R&D.

Patient stories and lived experience

Behind the pharmacology and revenue numbers are patients whose daily routines change because of Stelara. Take Michael, a 38?year?old software developer from Ohio with severe plaque psoriasis. Before switching to Stelara, he describes his elbows and knees as "chalky and cracked," leaving flakes on his dark office chair and drawing curious looks during summer meetings. After several months on the biologic, his plaques thinned, redness faded and he began wearing short sleeves again to client visits. That behavioral shift matters for workplace confidence as much as any clinical score.

Similarly, in inflammatory bowel disease, patients often recount the difference between frequent urgent trips to the restroom and being able to sit through an entire movie without discomfort. In one Chicago support group, a young woman with Crohn’s disease described her induction infusion: the antiseptic smell in the outpatient suite, the soft hiss of the blood pressure cuff, the nurse quietly adjusting the drip rate on the IV pump. By the time the clear bag had emptied, she felt no dramatic change — but weeks later, her stool frequency and abdominal pain had meaningfully dropped. Those concrete experiences shape how patients judge whether a biologic is "worth it," far more than chemical diagrams or Kaplan?Meier curves.

Label evolution and pediatric use

Stelara’s US label has expanded over time as new studies supported efficacy in additional populations. After initial approvals in adult psoriasis, the FDA cleared use in adolescent patients with moderate to severe plaque psoriasis, granting dermatologists a new option for teenagers whose disease severely affected social life and school performance. J&J adolescent indication release Later, approvals in pediatric Crohn’s disease extended its reach further into younger age groups, underscoring Johnson & Johnson’s investment in trials that require careful ethical and logistical planning.

Pediatric dosing and monitoring are nuanced, and clinicians like Dr. Sarah Kim, a pediatric gastroenterologist, stress the importance of explaining the therapy in age?appropriate ways. She talks about Stelara as a "shield" that helps calm an overactive gut immune system, using simple metaphors rather than abstract immunology terms. In infusion rooms, child?friendly touches — colorful murals, stuffed animals, flavored ice chips — soften the clinical environment and make the clear fluid dripping from the Stelara bag seem less intimidating.

Manufacturing and supply reliability

Producing ustekinumab requires sophisticated biologics manufacturing, including cell culture systems, purification steps and extensive quality controls. Johnson & Johnson operates large?scale facilities that adhere to current Good Manufacturing Practice (cGMP) standards, and regulators audit these plants regularly to verify sterility, potency and consistency. Janssen manufacturing overview

From the clinician perspective, what matters is that the drug simply arrives as ordered. Over the last several years, Stelara has not been among the biologics frequently flagged for US supply disruptions, and specialty pharmacies typically report steady inventory. That reliability plays into prescriber confidence: few things frustrate a gastroenterologist more than choosing a therapy based on clinical fit only to learn it is backordered. Here, Johnson & Johnson’s scale in biologics production supports the company’s reputation as a dependable supplier.

Investor context and Johnson & Johnson stock

For US retail investors, Stelara is one of the concrete products sitting behind the ticker symbol JNJ. It has contributed significantly to Johnson & Johnson’s pharmaceutical segment growth and cash flow, but its long?running success also means that biosimilar erosion is a real medium?term topic in earnings calls and analyst models. CNBC earnings analysis Shares of Johnson & Johnson (NYSE: JNJ) have reflected both the strength of its current immunology portfolio and market questions about how smoothly the company will transition from originator?dominated revenues to a mix that includes more next?generation agents and, eventually, competition from biosimilars.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.